Monday, February 16, 2026 2/16/2026

Advanced Image Analysis Tools for Diabetic Retinopathy Telemedicine Application

Award Number: R44EY026864
ORGANIZATION: NATIONAL EYE INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 08/01/2016
PERIOD OF PERFORMANCE END DATE: 07/31/2018

Group Awards By:

View Award Description

Advanced Image Analysis Tools for Diabetic Retinopathy Telemedicine Application - DESCRIPTION (provided by applicant): In this Phase IIB application, we propose to commercialize and bring to market EyeArt, a fully automated, high throughput, retinal image analysis based diabetic retinopathy (DR) screening tool (which has been developed and already validated in bench tests on very large real-world data) by conducting formal clinical trials and integrating it into several clinical information systems. With its fully automated use, high throughput capability (can analyze several thousands of patient cases in just a few hours), scalable architecture, and ability to seamlessly integrate into clinical workflows, EyeArt will aid the expansion of DR screening and help bridge the exponentially growing disparity between the number of diabetic patients and the number of eye care providers. DR is a common microvascular complication of diabetes affecting 80% of all diabetic patients. Even though vision loss due to DR is preventable by early detection and treatment, it is the one of the leading global causes of preventable blindness primarily due to the lack of easy access to eye care providers. Automated DR screening is the only way to make DR screening more accessible to the large and growing population of diabetic patients, currently 29 million in the US and 387 million world-wide and expected to grow to 110 million and 592 million respectively by 2030. To help reduce risk of DR vision loss in the diabetic population, EyeArt uses advanced image analysis algorithms to make DR screening more efficient, cost-effective, and more accessible. EyeArt has been validated and shown to have high screening sensitivity (safety) and efficacy on multiple large real-world datasets including one with over 54,000 patient cases (and 434,000 images) obtained from EyePACS, a DR telescreening system with over 360 sites in the US and elsewhere. Eyenuk has received ISO 13485 certification as a medical device manufacturer and EyeArt has received CE Marking and is commercially available in Europe. Going forward, we will clinically validate EyeArt in formal clinical trials and integrate it into clinical informatio systems to enable EyeArt's seamless incorporation into existing clinical workflows. This will pave the way for EyeArt's availability to the US DR screening market and reduce the burden on clinical resources by improving health care productivity. This will help increase the DR screening conformance in the diabetic population and thus help in reducing and ultimately eliminating vision loss due to DR through early detection and treatment.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2020 ( Subtotal = $0 )
2020	2017	EYENUK, INC.	5850 CANOGA AVE STE 250	WOODLAND HILLS	CA	91367	LOS ANGELES	USA	Vision Research	000	6	11/19/2019	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2017 ( Subtotal = $513,223 )
2017	2017	EYENUK, INC.	21860 BURBANK BLVD STE 160	WOODLAND HILLS	CA	91367	LOS ANGELES	USA	Vision Research	000	6	8/17/2017	NON-COMPETING CONTINUATION	$513,223
														Subtotal = $513,223

Issue Date FY: 2016 ( Subtotal = $984,026 )
2016	2016	EYENUK INC	22130 CLARENDON STREET	SAN LUIS OBISPO	CA	91367		USA	Vision Research	001	5	8/11/2016	COMPETING CONTINUATION	$85,837
2016	2016	EYENUK INC	22130 CLARENDON STREET	SAN LUIS OBISPO	CA	91367		USA	Vision Research	002	5	9/1/2016	COMPETING CONTINUATION	$24,024
2016	2016	EYENUK INC	22130 CLARENDON STREET	SAN LUIS OBISPO	CA	91367		USA	Vision Research	000	5	7/20/2016	COMPETING CONTINUATION	$874,165
														Subtotal = $984,026

Grand Total All Awards = $1,497,249

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Advanced Image Analysis Tools for Diabetic Retinopathy Telemedicine Application

Award Number: R44EY026864

ORGANIZATION: NATIONAL EYE INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 08/01/2016

PERIOD OF PERFORMANCE END DATE: 07/31/2018

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer